



Cite this: *Org. Biomol. Chem.*, 2017, **15**, 7422

Received 20th July 2017,
Accepted 11th August 2017
DOI: 10.1039/c7ob01786c
rsc.li/obc

Total synthesis and mass spectrometric analysis of a *Mycobacterium tuberculosis* phosphatidylglycerol featuring a two-step synthesis of (*R*)-tuberculostearic acid†

Satvika Burugupalli, Mark B. Richardson and Spencer J. Williams *

We report the total synthesis of (*R*)-tuberculostearic acid-containing *Mycobacterium tuberculosis* phosphatidylglycerol (PG). The approach features a two-step synthesis of (*R*)-tuberculostearic acid, involving an (*S*)-citronellyl bromide linchpin, and the phosphoramidite-assisted assembly of the full PG structure. Collision-induced dissociation mass spectrometry of two chemically-synthesized PG acyl regioisomers revealed diagnostic product ions formed by preferential loss of carboxylate at the secondary (sn-2) position.

Introduction

Phosphatidylglycerols are phospholipids produced by a wide range of organisms including bacteria, fungi, plants and animals.¹ Within animal cells PG is mainly found in the mitochondrial membranes,² and is believed to be released into the cellular milieu only upon cellular damage or stress. PGs are also produced by a wide range of bacteria, including important human pathogens such as *Listeria*, *Streptococcus*, and *Mycobacterium tuberculosis* (*Mtb*). PGs can be presented on several antigen presenting proteins of the cluster of differentiation 1 (CD1) class, specifically CD1b³ and CD1d,^{4,5} where they are recognized by natural killer T cells and lipid-reactive T cells. Thus PGs appear to be a molecular signature allowing immune recognition of bacterial infection or damaged self.

In mycobacteria, PG is an intermediate in the biosynthesis of lysinylated PG,⁶ phosphatidylinositol,⁷ and cardiolipin.^{7,8} It has been proposed that PG is synthesized in two steps (Fig. 1). Step 1 is catalyzed by phosphatidylglycerophosphate synthetase (PgsA3), which catalyzes the phosphatidylation of glycerol-3-phosphate by CDP-diacylglycerol to afford phosphatidylglycerophosphate;⁷ and step 2 which involves the dephosphorylation of phosphatidylglycerophosphate to afford PG, by a phosphatidylglycerophosphatase. *Mtb* PG occurs as a range of lipofoms including an abundant species that bears (*R*)-tuberculostearic acid (*R*-TBSA) at the sn-1 position, and palmitic acid at the sn-2 position,⁴ a decoration that matches that of other




Fig. 1 Structure of *Mycobacterium tuberculosis* (*Mtb*) TBSA-containing phosphatidylglycerol (PG).

phosphatidyl-containing lipids⁹ such as phosphatidylethanolamine,¹⁰ and phosphatidylinositol mannosides.¹¹ Possibly because of its role as a biosynthetic intermediate, *Mtb* PG occurs at low levels and the challenges of its isolation⁴ from the natural source are compounded by the pathogenicity and low growth rate of *Mtb*. Recent work has shown that *Mtb* PG can be presented by the CD1d antigen presenting molecule to natural killer T cells that display 'type II' T cell receptors.⁴ Type II NKT cells are distinguished from their better studied type I variants, by lacking reactivity to the prototypical NKT ligand α -galactosyl ceramide, and through possessing a diverse array of $\alpha\beta$ chains that comprise the T cell receptor.¹² While most studies have focused on type I NKT cells, type II NKT cells are more abundant in humans, and are functionally distinct from type I NKT cells.¹³ However, studies of type II NKT cells have been limited by a lack of well-defined lipid antigens.

Herein we report the total synthesis of the TBSA-containing *Mtb* PG (**1**) using phosphoramidite chemistry. As part of this effort we have devised the shortest synthesis yet reported of *R*-TBSA (**2**) in just two steps from commercially available (*S*)-citronellyl bromide, and its incorporation into *Mtb* PG. Finally, we demonstrate that collision-induced dissociation mass spectrometry of chemically-synthesized PG regioisomers results in

School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia 3010.

E-mail: sjwill@unimelb.edu.au

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ob01786c




the formation of diagnostic fragment ions that have utility in the structural characterization of PGs.

Results and discussion

Synthesis of (*R*)-tuberculostearic acid

Numerous syntheses of *R*-TBSA have been reported, using chiral pool sources,^{17,19,20} chiral auxiliaries,²¹ catalytic enantioselective induction,^{10,18} and resolution methods^{14–16} (Table 1). The most efficient synthesis reported to date is that of Roberts and Baird who prepared TBSA in four steps from (*S*)-citronellyl bromide, in a route involving stepwise elongations using copper(i)-catalyzed cross-coupling and Wittig extension.²² We were inspired by this use of citronellyl bromide as a linchpin, and anticipated that diverting the cross-coupled intermediate into a Grubbs-cross-metathesis/hydrogenation process could provide further synthetic abbreviation. Thus, according to the reported method,²² copper(i)-catalyzed cross-coupling of hexyl magnesium bromide with (*S*)-citronellyl bromide afforded the alkene **3** (Scheme 1). Initially, a 1 : 1 mixture of ethyl 6-heptenoate and **3** were reacted in the presence of Hoveyda–Grubbs II catalyst, affording a 58% yield of an *E/Z* mixture of cross-coupled alkenes. We next attempted a direct tandem cross-metathesis/hydrogenation reaction.³⁹ Use of a 1 : 1 mixture of alkenes afforded a 48% yield of ethyl *R*-TBSA, which could be improved to 76% by using a 3 : 1 ratio of ethyl heptenoate/**3**. Saponification of ethyl *R*-TBSA afforded *R*-TBSA (**2**) in three steps. Encouraged by these results, we next enacted a two-step synthesis of *R*-TBSA by employing a 3 : 1 ratio of 6-heptenoic acid/**3** under the same conditions, which directly afforded *R*-TBSA in 73% yield.













Scheme 1 Two-step synthesis of (*R*)-tuberculostearic acid.

Synthesis of phosphatidylglycerols

Reported methods for the synthesis of PGs include chemo-enzymatic methods,²³ and purely chemical approaches;²⁴ however, the reported chemical methods typically employ highly moisture sensitive POCl₃ as a phosphorylation reagent and do not allow regioselective introduction of two different acyl groups. In devising an approach to *Mtb* PG, we elected to utilize contemporary phosphoramidite chemistry, which has been widely applied in the synthesis of oligonucleotides,²⁵ phosphatidylinositols,²⁶ and cardiolipin.²⁷


We chose to prepare **1**, and analogues lacking the 10-methyl group with alternate arrangements of the fatty acyl groups. For the construction of the requisite diacylglycerols, we employed the approach of Minnaard, which proceeds with high regioselectivity and without acyl group migration.¹⁸ Accordingly, opening of benzyl (*R*)-glycidyl ether (**5**) with palmitic acid, stearic acid, or *R*-TBSA using Jacobsen pre-catalyst **C1**,²⁸ followed by esterification with a second fatty acid and DCC/DMAP, gave the diesters **6a–c** (Scheme 2). Hydrogenolysis

Table 1 Previous synthetic approaches to (*R*)-tuberculostearic acid

Starting material/ key intermediate	Approach/steps	Ref.	Starting material/ key intermediate	Approach/steps	Ref.
 (<i>R</i>)-2-methyldecanol	Chiral resolution/ 10 steps ^a	Prout, 1948 ¹⁴	 bromocasylate	Chiral resolution/7 steps	Hahn, 2015 ¹⁵
 methyl (<i>R</i>)-β-methylglutarate	Chiral resolution/ 9 steps	Linstead, 1951 ¹⁶	 isopropyl 10-undecenoate	Catalytic enantioselective induction/6 steps ^b	Feringa, Minnaard, 2010 ¹⁰
 (<i>S</i>)-citronellol	Chiral pool/ 8 steps	Larsen, 2007 ¹⁷	 nonanal	Catalytic enantioselective induction/5 steps	Minnaard, 2013 ¹⁸
 Roche ester	Chiral pool/ 7 steps	Seeberger, 2006 ¹⁹	 Roche ester	Chiral pool/5 steps	Hung, 2015 ²⁰
 (<i>R</i>)-oxazolidinone	Chiral auxiliary/ 7 steps	Williams, 2013 ²¹	 (<i>S</i>)-citronellyl bromide	Chiral pool/4 steps	Baird, 2006 ²²

^a (*R*)-2-Methyldecanol was synthesized from bromooctane in 5 steps by resolution of an intermediate brucine salt. ^b Isopropyl 10-undecenoate can be synthesized in one step from commercially-available undecylenic acid.






Scheme 2 Preparation of diacylglycerols.

of the benzyl ether afforded the diacylglycerols **7a–c**, which were used immediately without purification in the next step.

Assembly of the PG structure relied upon the use of a phosphordiamidite linchpin, benzyl bis(*N,N*-diisopropyl)phosphordiamidite (Scheme 3).^{17,29} Reaction of the diacylglycerols **7a–c** with this phosphordiamidite, catalyzed by diisopropyl ammonium tetrazolide (DIPAT), a weak acid that does not activate the product,²⁵ afforded the unstable phosphoramidites **8a–c**. Compounds **8a–c** were purified by a quick passage over alumina to remove any residual reactant or reagents, and then immediately subjected to a second phosphitylation reaction with dibenzylglycerol **9**, catalyzed by 1*H*-tetrazole. Upon consumption of the phosphoramidate, *t*-BuOOH was added to oxidize the intermediate phosphite to the protected PGs **10a–c**.

Scheme 3 Preparation of *Mtb* PG 1 and analogues.

Finally, hydrogenolysis of the benzyl groups provided *Mtb* PG **1**, and analogues **11a** and **11b**.

Collision-induced dissociation mass spectrometry of phosphatidylglycerols

Early studies reported that negative-ion fast-atom bombardment or electrospray-ionization with collision-induced dissociation/tandem mass spectrometry of phosphatidylethanolamine (PE) and PG results in fragmentation to provide high abundance fatty acid carboxylate (RCO₂[−]) fragment ions.^{30,31} These studies revealed similar fragmentation pathways for PE and PG, and showed that regioisomeric PEs fragment in a characteristic way to produce RCO₂[−] ions for which those derived from the sn-2 position are of greater intensity, thereby allowing structural characterization of fatty acyl regiochemistry.^{10,31} Subsequently, it was shown that CID/MS-MS of PG occurs with similar results, producing RCO₂[−] ions in which




Fig. 2 Multistage mass spectrometry (MS²) experiments involving the collision-induced dissociation of negative ions formed by electro-spray ionization.[†] (a) MS² spectrum of deprotonated **11a** (C₁₆/C₁₈). (b) MS² spectrum of deprotonated **11b** (C₁₈/C₁₆). (c) MS² spectrum of deprotonated **1**. (d) Fragmentation of compound **1**. See Experimental for details.



those from the sn-2 position are more abundant, in what has been described as a charge-driven process.^{32,33} In order to confirm these fragmentation patterns we studied the chemically synthesized regioisomers **11a** and **11b** in negative ion CID/MS² experiments using electro-spray ionization. Fragmentation of the parent anions $[M - H]^-$ (m/z 749.5) formed from the regioisomers **11a** (C₁₆/C₁₈) and **11b** (C₁₈/C₁₆), yielded characteristic fatty acid carboxylate (RCO₂[−]) fragment ions at m/z 255.2 and 283.3 (Fig. 2a and b). In each case the more abundant ion is that derived from the fatty acid located in the sn-2 position. This work confirms that CID-induced fragmentation patterns can be used to identify the structures of asymmetrical PG molecules. Fig. 2c shows the CID-MS² spectrum of **1**, revealing that fragmentation of the parent ion $[M - H]^-$ (m/z 763.5) affords daughter ions at m/z 255.2 and 297.3. Here, the most abundant fragment (m/z 255.2) is that derived from the palmitic acid located at the sn-2 position. We note that these and earlier observations for CID-MS of PGs differ from those for the structurally-related phosphatidylinositols³² and phosphatidylinositolmannosides,^{11,17} which under similar conditions fragment by neutral loss of fatty acids and fatty acid ketenes in a diagnostic way. While these systems also yield RCO₂[−] fragment ions, their relative intensities do not reflect the regiochemistry of their location on the phosphatidyl group because other pathways also yield these ions in abundances that are sensitive to the applied collision energy.³²

Conclusions

In this work we disclose the first total synthesis of *Mtb* PG **1**, and analogues **11a** and **11b**. Our approach includes the most concise preparation of *R*-TBSA reported to date. We note that while *Mtb* PG has only been studied in the context of a CD1d-presented lipid antigen, other closely related PGs from mammals, *Escherichia coli*, *Corynebacterium glutamicum* and *Listeria monocytogenes* have been identified as CD1b-presented lipid antigens.³ Access to synthetic *Mtb* PG **1** and analogues **11a** and **11b** should support studies to understand its immunological properties, and investigation of the effect of the branched-methyl group in the fatty acyl chain. Collision-induced dissociation mass spectrometry analysis confirms the desired acylation patterns in our synthetically acquired materials, and provides a foundation for structural analyses of mycobacterial PGs.

Experimental

General methods

Proton (¹H NMR, 400 or 500 MHz), proton-decoupled carbon-13 (¹³C NMR, 100 or 125 MHz), and phosphorus-31 (³¹P NMR, 202 MHz) nuclear magnetic resonance spectra were obtained in deuteriochloroform or methanol-d₄ (CD₃OD) with residual protonated solvent or solvent carbon signals as internal standards. Abbreviations for multiplicity are s, singlet; d, doublet; t,

triplet; q, quartet; m, multiplet. Flash chromatography was carried out on silica gel 60 according to the procedure of Still *et al.*³⁴ Chromatography on alumina was performed on a column using neutral, activated aluminium oxide (50–200 micron, Acros Organics). Analytical thin layer chromatography (t.l.c.) was conducted on aluminium-backed 2 mm thick silica gel 60 F₂₅₄ and chromatograms were visualized with ceric ammonium molybdate (Hanesian's stain), potassium permanganate or 5% H₂SO₄/MeOH, with charring as necessary. High resolution mass spectra (HRMS) were obtained using an ESI-TOF-MS; all samples were run using 0.1% formic acid. Dry CH₂Cl₂, THF, and Et₂O were obtained from a dry solvent apparatus (Glass Contour of SG Water, Nashua, USA) as per the procedure of Pangborn *et al.*³⁵ Dry DMF was dried over 4 Å molecular sieves. Pet. spirits refers to petroleum ether, boiling range 40–60 °C.

Synthesis of (*R*)-tuberculoostearic acid (**2**)

(*R*)-2,6-Dimethyltetradecene (**4**). See: Roberts and Baird.²² hexylmagnesium bromide (3.14 ml, 4.56 mmol) (2.0 M in Et₂O) was added to a solution of (*S*)-citronellyl bromide (0.23 ml, 1.14 mmol) in dry Et₂O (2.3 ml) at −78 °C followed by dilithium tetrachlorocuprate (Li₂CuCl₄) (0.1 M in THF) (1.94 ml, 0.12 mmol). The solution was allowed to warm to room temperature and stirred for 36 h. The reaction mixture was quenched with sat. aq. NH₄Cl, extracted with Et₂O, and the organic phase washed with brine, dried (MgSO₄) and concentrated under reduced pressure. Flash chromatography (0.5% Et₂O:petroleum ether) of the residue afforded **4** as a colorless oil (240 mg, 95%); $[\alpha]_D^{22} +0.75$ (c 0.5 in CHCl₃) (lit.²² $[\alpha]_D^{25} +1.5$ in CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 0.88–0.83 (6 H, m, 2 × CH₃), 1.15–1.06 (2 H, m, CH₂), 1.31–1.22 (20 H, m, 10 × CH₂), 1.60 (3 H, s, CH₃), 1.68 (3 H, s, CH₃), 1.95 (2 H, dd, J = 6.8, 13.7 Hz, CHCH₂), 5.10 (1 H, t, J = 7.0 Hz, CH=C); ¹³C NMR (101 MHz, CDCl₃) δ 14.2, 17.7, 19.2, 22.8, 25.7, 27.1, 29.5, 29.8, 30.1, 32.0, 32.5, 37.1, 37.3, 125.2, 131.0; HRMS calcd for C₁₆H₃₂ $[M + H]^+$ 225.2538, found 225.2534.

Ethyl (*R*)-10-methyloctadecanoate. Hoveyda–Grubbs 2nd generation catalyst (HG-II) (2.8 mg, 4 mol%) was added to a solution of **4** (250 mg, 0.11 mmol) and ethyl heptenoate (59 mg, 0.33 mmol) in dry dichloromethane (1.14 ml) and stirred for 24 h under reflux. Upon consumption of starting material, the reaction mixture was concentrated under reduced pressure. EtOAc (5.0 ml) was added to the residue and the solution was subjected to hydrogenation under high pressure (37 bar) in a Buchi® hydrogenator overnight at room temp after which the solvent was removed under reduced pressure. Flash chromatography (2% Et₂O/petroleum spirits) of the crude mixture afforded the title compound as a colourless oil (28 mg, 76%); $[\alpha]_D^{22} -0.14$ (c 0.5 in CHCl₃) (lit.¹⁴ $[\alpha]_D^{25} -0.16$ in CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 0.82 (3 H, d, J = 6.5 Hz, CHCH₃), 0.87 (3 H, t, J = 6.8 Hz, CH₃), 1.10–1.03 (2 H, m, CH₂), 1.31–1.20 (28 H, m, 12 × CH₂, 1 × CH, COOCH₂CH₃), 1.61 (2 H, d, J = 7.1 Hz, COCH₂CH₂), 2.27 (2 H, t, J = 7.6 Hz, COCH₂), 4.11 (2 H, d, J = 7.1 Hz, C=OOCH₂); ¹³C NMR (101 MHz, CDCl₃) δ 14.2, 14.4, 19.8, 22.8, 25.1, 27.1, 27.2, 29.3, 29.4, 29.5, 29.6, 29.8, 30.0, 30.1, 32.0, 32.8, 32.8, 34.5, 37.2,



60.2, 174.0 (C=O); HRMS calcd for $C_{21}H_{42}O_2$ $[M + H]^+$ 327.3218, found 327.3220.

(R)-Tuberculostearic acid ((R)-10-methyloctadecanoic acid) (2)

From ethyl (R)-10-methyloctadecanoate. 2 M KOH (0.76 ml, 1.5 mmol) was added to a solution of the ethyl ester (50 mg, 0.153 mmol) in MeOH/THF (1 : 1, 0.8 ml) and stirred under reflux overnight. The solution was acidified with aq. citric acid (1 M), extracted with EtOAc, and the organic phase washed with brine, dried ($MgSO_4$) and concentrated under reduced pressure to afford 2 as a colorless oil (44 mg, 97%); $[\alpha]_D^{25}$ -0.9 (c 1.0 in $CHCl_3$) (lit.²² $[\alpha]_D^{25}$ -0.34 in $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$) δ 0.83 (3 H, d, J = 6.5 Hz, $CHCH_3$), 0.88 (3 H, t, J = 6.8 Hz, CH_2CH_3), 1.12–1.04 (2 H, m, CH_2), 1.36–1.21 (25 H, m, $12 \times CH_2$, $1 \times CH$), 1.67–1.59 (2 H, m, $OCOCH_2CH_2$), 2.35 (2 H, t, J = 7.5 Hz, $OCOCH_2$); ^{13}C NMR (101 MHz, $CDCl_3$) δ 14.2, 19.8, 22.8, 24.8, 27.1, 27.2, 29.2, 29.4, 29.5, 29.6, 29.8, 30.0, 30.1, 32.0, 32.8, 34.0, 37.2, 179.5; HRMS calcd for $C_{18}H_{36}O_2$ $[M + H]^+$ 285.2749, found 285.2747.

From alkene 4. HG-II (2.80 mg, 4 mol%) was added to a solution of 4 (25 mg, 0.114 mmol) and heptenoic acid (59 mg, 0.334 mmol) in dry CH_2Cl_2 (1.14 ml) and stirred for 24 h under reflux. The reaction mixture was concentrated under reduced pressure. EtOAc (5.0 ml) was added to the residue and the solution was subjected to hydrogenation under high pressure (37.5 bar) in a Buchi® hydrogenator overnight at room temperature after which solvent was removed under reduced pressure. Flash chromatography (2% Et_2O /petroleum spirits) of the crude mixture afforded 2 as a colorless oil (25 mg, 73%).

Synthesis of diacylglycerols

3-O-Benzyl-1-O-((R)-10-methyloctadecanoyl)-2-O-palmitoyl-sn-glycerol (6c). A solution of (R)-TBSA 2 (100 mg, 335 μ mol) and Co[salen] C1 (4.0 mg, 2 mol%) in Et_2O (1 ml) was stirred under an oxygen balloon for 10 min. The solvent was evaporated under vacuum to afford a brown residue. THF (0.2 ml) and Hünig's base (58 μ l, 372 μ mol) was added to the residue, and the mixture was stirred for 5 min. (R)-Glycidyl benzyl ether (56.7 μ l, 372 μ mol) was added and the resulting mixture was stirred overnight at room temperature followed by removal of solvents *in vacuo*. Heptane (800 μ l), palmitic acid (114 mg, 446 μ mol) and DMAP (2.27 mg, 18.6 μ mol, 5 mol%) were added to the resulting residue. The mixture was cooled to 0 °C, followed by addition of DCC (91.9 mg, 446 μ mol) and stirred overnight. The solvent was removed *in vacuo* and the residue was subjected to flash chromatography (10% Et_2O : pentane) to afford the title compound as a colorless thick liquid (178 mg, 77%); $[\alpha]_D^{25}$ +6.2 (c = 0.5, $CHCl_3$), $[\alpha]_D^{23}$ lit.¹⁹ +5.45 (c = 3.9, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$) δ 0.83 (3 H, d, J = 6.5 Hz, CCH_3 (TBSA)), 0.88 (6 H, t, J = 6.8 Hz, $2 \times CH_3$), 1.07 (2 H, m, CH_2 (TBSA)), 1.25 (48 H, m, $24 \times CH_2$), 1.60 (4 H, m, $2 \times COCH_2CH_2$), 2.25–2.34 (4 H, m, $2 \times COCH_2$), 3.59 (2 H, d, J = 5.2 Hz, H3a,3b), 4.19 (1 H, dd, J = 11.9, 6.4 Hz, H1a), 4.34 (1 H, dd, J = 11.9, 3.8 Hz, H1b), 4.50–4.58 (2 H, m, CH_2Ph), 5.24 (1 H, m, H2), 7.27–7.37 (5 H, m, Ph); ^{13}C NMR (125 MHz, $CDCl_3$)

δ 14.2, 19.8, 22.8, 25.0, 25.1, 27.2, 29.2, 29.2, 29.4, 29.5, 29.6, 29.6, 29.8, 30.1, 30.1, 32.0, 32.9, 34.2, 34.4, 37.2, 62.8, 68.4, 70.1, 73.4, 127.7, 127.9, 128.5, 137.8 (Ph), 173.2, 173.5 (C=O); HRMS: calcd for $C_{45}H_{80}O_5$ $[M + H]^+$ 701.6039, found 701.6038.

3-O-Benzyl-1-O-palmitoyl-2-O-stearoyl-sn-glycerol (6a).

Synthesized as for 6c, 250 mg (0.36 mmol, 66%). $[\alpha]_D^{25}$ +5.6 (c = 0.5, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$) δ 0.88 (6 H, t, J = 6.8 Hz, $2 \times CH_3$), 1.27 (48 H, m, $24 \times CH_2$), 1.60 (4 H, m, $2 \times COCH_2CH_2$), 2.25–2.34 (4 H, m, $2 \times COCH_2$), 3.59 (2 H, d, J = 5.2 Hz, H3a,3b), 4.19 (1 H, dd, J = 11.9, 6.4 Hz, H1a), 4.34 (1 H, dd, J = 11.9, 3.8 Hz, H1b), 4.50–4.58 (2 H, m, CH_2Ph), 5.24 (1 H, m, H2), 7.28–7.37 (5 H, m, Ph); ^{13}C NMR (101 MHz, $CDCl_3$) δ 14.2, 22.8, 25.0, 25.1, 29.2, 29.2, 29.4, 29.5, 29.6, 29.8, 29.8, 32.0, 34.2, 34.4, 62.8, 68.4, 70.1, 73.4, 127.7, 127.9, 128.5, 137.8, 173.2, 173.5; HRMS: calcd for $C_{44}H_{78}O_5$ $[M + H]^+$ 687.5883, found 687.5884.

3-O-Benzyl-1-O-stearoyl-2-O-palmitoyl-sn-glycerol (6b).

Synthesized as for 6c, 62 mg (0.093 mmol, 64%). $[\alpha]_D^{25}$ +5.8 (c = 0.5, $CHCl_3$), lit.³⁶ $[\alpha]_D^{23}$ +5.4 (c = 1.63, $CHCl_3$); 1H NMR (400 MHz, $CDCl_3$) δ 0.88 (6 H, t, J = 6.8 Hz, $2 \times CH_3$), 1.27 (48 H, m, $24 \times CH_2$), 1.60 (4 H, m, $2 \times COCH_2CH_2$), 2.25–2.34 (4 H, m, $2 \times COCH_2$), 3.59 (2 H, d, J = 5.2 Hz, H3a,3b), 4.19 (1 H, dd, J = 11.9, 6.4 Hz, H1a), 4.34 (1 H, dd, J = 11.9, 3.8 Hz, H1b), 4.50–4.58 (2 H, m, CH_2Ph), 5.24 (1 H, m, H2), 7.28–7.37 (5 H, m, Ph); ^{13}C NMR (101 MHz, $CDCl_3$) δ 14.2, 22.8, 25.0, 25.1, 29.2, 29.2, 29.4, 29.5, 29.6, 29.8, 29.8, 32.0, 34.2, 34.4, 62.8, 68.4, 70.1, 73.4, 127.7, 127.9, 128.5, 137.8 (Ph), 173.2, 173.5 (C=O); HRMS: calcd for $C_{44}H_{78}O_5$ $[M + H]^+$ 687.5883, found 687.5884.

1-O-((R)-10-Methyloctadecanoyl)-2-O-palmitoyl-sn-glycerol (7c).

A mixture of 6c (65 mg, 0.089 mmol) and $Pd(OH)_2$ on carbon (20%, 40 mg, 0.285 mmol) in ethanol (3 ml) was stirred under hydrogen at 10 bar for 2 h. The reaction mixture was filtered through Celite and the solvent removed *in vacuo* to afford the product as a colorless liquid (61 mg, 99%). The compound was used directly without delay or purification. 1H NMR (400 MHz, $CDCl_3$) δ 0.83 (3 H, d, J = 6.5 Hz, CCH_3 (TBSA)), 0.88 (6 H, t, J = 6.8 Hz, $2 \times CH_3$), 1.08 (2 H, m, CH_2 (TBSA)), 1.27 (48 H, m, $24 \times CH_2$), 1.62 (4 H, m, $2 \times COCH_2CH_2$), 2.30–2.37 (4 H, m, $2 \times COCH_2$), 3.73 (2 H, d, J = 5.2 Hz, H3a,3b), 4.24 (1 H, dd, J = 11.9, 5.6 Hz, H1a), 4.32 (1 H, dd, J = 11.9, 4.6 Hz, H1b), 5.06–5.11 (1 H, m, H2).

1-O-Palmitoyl-2-O-stearoyl-sn-glycerol (7a). Synthesized as for 7c, 30.4 mg (98%). 1H NMR (500 MHz, $CDCl_3$) δ 0.88 (6 H, t, J = 7.0 Hz, $2 \times CH_3$), 1.27–1.34 (48 H, m, $24 \times CH_2$), 1.62 (4 H, m, $2 \times COCH_2CH_2$), 2.30–2.37 (4 H, m, $2 \times COCH_2$), 3.73 (2 H, dd, J = 5.0, 1.4 Hz, H3a,3b), 4.23 (1 H, dd, J = 11.9, 5.7 Hz, H1a), 4.32 (1 H, dd, J = 11.9, 4.5 Hz, H1b), 5.06–5.11 (1 H, m, H2).

1-O-Stearoyl-2-O-palmitoyl-sn-glycerol (7b). Synthesized as for 7c, 40.2 mg (96%). 1H NMR (500 MHz, $CDCl_3$) δ 0.88 (6 H, t, J = 7.0 Hz, $2 \times CH_3$), 1.27–1.34 (48 H, m, $24 \times CH_2$), 1.62 (4 H, m, $2 \times COCH_2CH_2$), 2.30–2.37 (4 H, m, $2 \times COCH_2$), 3.73 (2 H, dd, J = 5.0, 1.4 Hz, H3a,3b), 4.23 (1 H, dd, J = 11.9, 5.7 Hz, H1a), 4.32 (1 H, dd, J = 11.9, 4.5 Hz, H1b), 5.06–5.11 (1 H, m, H2).



Synthesis of phosphatidylglycerols

***O*-Benzyl-*O*-(1-*O*-((*R*)-10-methyloctadecanoyl)-2-*O*-palmitoyl-*sn*-glycer-3-yl) *N,N*-diisopropylphosphoramidite (8c).**

Diisopropylammonium tetrazolide (34.1 mg, 0.199 mmol) was added to a solution of alcohol 7c (58.0 mg, 0.094 mmol) and benzyl bis(*N,N*-diisopropyl)phosphoramidite³⁷ (62.3 mg, 0.189 mmol) in dry CH₂Cl₂ at 0 °C under nitrogen. The reaction mixture was stirred for 30 min at 0 °C and 25 min at room temperature. The solvent was removed *in vacuo* and the residue was purified by column chromatography on alumina (5% EtOAc/petroleum ether) to afford the title compound as a colorless oil (50 mg, 85%); [α]_D²³ +5.4 (*c* = 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.83 (3 H, d, *J* = 6.6 Hz, CCH₃ (TBSA)), 0.88 (6 H, t, *J* = 6.9 Hz, 2 \times CH₃), 1.18 (2 H, m, CH₂), 1.17–1.20 (12 H, m, 2 \times CH(CH₃)₂), 1.23–1.35 (49 H, m, 24 \times CH₂, 1 \times CH), 1.57–1.62 (4 H, m, COCH₂CH₂), 2.21–2.31 (4 H, m, COCH₂), 3.60–3.81 (4 H, m, 2 \times CH(CH₃)₂, H3a,3b), 4.13–4.20 (1 H, m, H1a), 4.31–4.37 (1 H, m, H1b), 4.64–4.77 (2 H, m, CH₂Ph), 5.15–5.22 (1 H, m, H2), 7.30–7.41 (5 H, m, Ph); ¹³C NMR (75 MHz, CDCl₃) δ 14.2, 19.8, 22.8, 24.6, 24.7, 24.8, 25.0, 29.2, 29.4, 29.5, 29.6, 29.8, 29.8, 32.0, 34.3, 43.1, 43.2, 61.6, 61.7, 61.9, 62.6, 63.2, 65.4, 65.6, 70.9 (N-CH), 127.0, 127.4, 128.3, 139.4 (Ph), 173.1, 173.5 (C=O); ³¹P NMR (202 MHz, CDCl₃) δ 148.8; HRMS-ESI: [M + H]⁺ calcd for C₅₁H₉₅O₆NP 848.6897; found 848.6885.

***O*-Benzyl-*O*-(1-*O*-((*R*)-10-methyloctadecanoyl)-2-*O*-palmitoyl-*sn*-glyceryl)-*O*-(2,3-di-*O*-benzyl-*sn*-glycer-1-yl)phosphate (10c).**

1*H*-Tetrazole (4.8 mg, 0.068 mmol) was added to a solution of phosphoramidite (42.0 mg, 0.049 mmol) and 2,3-di-*O*-benzyl-*sn*-glycerol 9³⁸ (10.7 mg, 0.0392 mmol) in dry CH₂Cl₂ (2 ml) at 0 °C under nitrogen. The reaction mixture was stirred for 15 min at 0 °C and 2 hours at room temperature. The reaction mixture was cooled to 0 °C and *t*-BuOOH (5 M in decane) (5 μ l, 0.0582 mmol) was added and stirred for 2 h warming to room temperature. Excess oxidant was quenched with sodium metabisulfite (1 M, 0.1 ml), the reaction mixture was diluted with CH₂Cl₂, extracted, dried (MgSO₄), filtered and concentrated. The residue was purified by column chromatography on silica gel (35% EtOAc/petroleum ether, 0.5% Et₃N) to afford the title compound as an oil (25 mg, 55%); [α]_D²⁴ 6.3 (*c* 0.25, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 0.83 (3 H, d, *J* = 6.6 Hz, CCH₃ (TBSA)), 0.88 (6 H, t, *J* = 6.9 Hz, 2 \times CH₃ (TBSA, palmitoyl)), 1.06–1.07 (2 H, m, CH₂), 1.26 (49 H, m, 24 \times CH₂, 1 \times CH), 1.57 (4 H, m, 2 \times COCH₂CH₂), 2.26 (4 H, m, 2 \times COCH₂), 3.56 (2 H, t, *J* = 5.6 Hz, H3'a,3'b), 3.77 (1 H, m, H2'), 4.03–4.16 (4 H, m, H3a,3b,1'a,1'b), 4.23 (2 H, m, H1a,1b), 4.51 (2 H, d, *J* = 4.8 Hz, CH₂Ph), 4.60–4.67 (2 H, m, CH₂Ph), 5.02–5.05 (2 H, m, CH₂Ph), 5.16 (1 H, m, H2'), 7.32 (15 H, m, Ph); ¹³C NMR (126 MHz, CDCl₃) δ 14.2, 19.8, 22.8, 24.9, 27.2, 29.2, 29.2, 29.4, 29.5, 29.6, 29.7, 29.8, 30.1, 30.2, 32.0, 32.9, 34.1, 34.2, 37.2, 61.8, 65.5, 67.3, 67.3, 69.1, 69.4, 69.4, 69.5, 69.6, 72.3, 73.6, 127.7, 127.8, 127.9, 128.0, 128.5, 128.5, 128.7 (Ph), 172.9, 173.3 (C=O); ³¹P NMR (202 MHz, CDCl₃) δ -1.01, -0.98; HRMS: [M + H]⁺ calcd for C₆₂H₉₉O₁₀P, 1035.7009; found 1035.7006.

Triethylammonium *O*-(1-*O*-((*R*)-10-methyloctadecanoyl)-2-*O*-palmitoyl-*sn*-glyceryl)-*O*-(*sn*-glycer-1-yl)phosphate (1). A mixture of Pd(OH)₂ on carbon (20%, 5 mg, 0.035 mmol), 10c (10 mg, 9.65 μ mol) in EtOAc: methanol (5 ml, 5:1) was stirred under hydrogen (20 bar) for 4 h at room temperature. The reaction mixture is filtered through a short plug of Celite to remove the catalyst. Triethylamine (5 μ l) was added to the filtrate and solvent removed under reduced pressure. The resulting residue was purified by flash chromatography (20% methanol: chloroform) to afford 1 as a colorless oil (9 mg, 98%); [α]_D²⁴ +5.8 (*c* 0.25, CHCl₃); ¹H NMR (500 MHz, CD₃OD:CDCl₃ (1:2)) δ 0.80 (3 H, d, *J* = 6.6 Hz, CCH₃ (TBSA)), 0.85 (6 H, t, *J* = 6.8 Hz, 2 \times CH₃ (TBSA, palmitoyl)), 1.03–1.06 (2 H, m, CH₂), 1.17–1.36 (62 H, m, 26 \times CH₂, 1 \times CH, HN(CH₂CH₃)₃), 1.57 (4 H, m, 2 \times COCH₂CH₂), 2.29 (4 H, dd, *J* = 15.6, 8.0 Hz, 2 \times COCH₂), 3.11 (4 H, q, *J* = 7.3 Hz, NH(CH₂CH₃)₃), 3.58 (2 H, s, H3'a,3'b), 3.76 (1 H, s, H2'), 3.90 (2 H, s, H1'a,1'b), 3.98 (2 H, s, H3a,3b), 4.15 (1 H, dd, *J* = 11.8, 6.5 Hz, H1b), 4.38 (1 H, d, *J* = 12.0 Hz, H1a), 5.20 (1 H, s, H2); ¹³C NMR (126 MHz, CD₃OD:CDCl₃ (1:2)) δ 14.2, 19.9, 23.0, 25.2, 25.2, 27.4, 29.5, 29.5, 29.7, 29.9, 29.9, 30.0, 30.3, 30.4, 32.3, 33.1, 34.4, 34.6, 37.4, 46.8, 62.9, 64.2, 67.1, 70.7, 71.4 (glycerol C), 174.0, 174.3 (C=O); ³¹P NMR (202 MHz, CD₃OD:CDCl₃ (1:2)) δ 4.78; HRMS: [M + H]⁺ calcd for C₄₇H₉₆NO₁₀P 866.6805; found 866.6806.

***O*-Benzyl-*O*-(1-*O*-(palmitoyl)-2-*O*-stearoyl-*sn*-glycer-3-yl) *N,N*-diisopropylphosphoramidite (8a).** Alcohol 7a (30 mg, 0.050 mmol) was treated as for the preparation of 8c to afford 8a (30.4 mg, 72%). [α]_D²⁴ +5.8 (*c* = 0.5, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 0.88 (6 H, t, *J* = 6.8 Hz, 2 \times CH₃), 1.17–1.20 (12 H, m, 2 \times CH(CH₃)₂), 1.23–1.35 (52 H, m, 26 \times CH₂), 1.57–1.62 (4 H, m, COCH₂CH₂), 2.21–2.31 (4 H, m, COCH₂), 3.60–3.67 (2 H, m, 2 \times CH(CH₃)₂), 3.69–3.75 (1 H, m, H3b), 3.76–3.81 (1 H, m, H3a), 4.13–4.20 (1 H, m, H1a), 4.34 (1 H, td, *J* = 12.2, 3.8 Hz, H1b), 4.63–4.79 (2 H, m, CH₂Ph), 5.18–5.19 (1 H, m, H2), 7.27–7.35 (5 H, m, Ph); ¹³C NMR (101 MHz, CDCl₃) δ 14.2, 22.8, 24.6, 24.7, 24.8, 25.0, 29.2, 29.4, 29.5, 29.6, 29.8, 29.8, 32.0, 34.3, 43.1, 43.2, 61.6, 61.7, 61.9, 62.6, 63.2, 65.4, 65.6, 70.9 (N-CH), 127.0, 127.4, 128.3, 139.4 (Ph), 173.1, 173.5 (C=O); ³¹P NMR (202 MHz, CDCl₃) δ 148.8; HRMS-ESI: [M + H]⁺ calcd for C₅₀H₉₂NO₆P 834.6696; found 834.6696.

***O*-Benzyl-*O*-(1-*O*-(stearoyl)-2-*O*-palmitoyl-*sn*-glycer-3-yl) *N,N*-diisopropylphosphoramidite (8b).** Alcohol 8a (36.0 mg, 0.60 mmol) was treated as for the preparation of 8c to afford 8b (29.8 mg, 58%). [α]_D²⁴ +5.5 (*c* 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 0.88 (6 H, t, *J* = 6.8 Hz, 2 \times CH₃), 1.17–1.20 (12 H, m, 2 \times CH(CH₃)₂), 1.23–1.35 (52 H, m, 26 \times CH₂), 1.57–1.62 (4 H, m, COCH₂CH₂), 2.21–2.31 (4 H, m, COCH₂), 3.58–3.83 (4 H, m, 2 \times CH(CH₃)₂, H3a,3b), 4.12–4.19 (1 H, m, H1a), 4.30–4.38 (1 H, m, H1b), 4.62–4.80 (2 H, m, CH₂Ph), 5.17–5.24 (1 H, m, H2), 7.27–7.35 (5 H, m, Ph); ¹³C NMR (75 MHz, CDCl₃) δ 14.2, 22.8, 24.6, 24.7, 24.8, 25.0, 29.2, 29.4, 29.5, 29.6, 29.8, 29.8, 32.0, 34.3, 43.1, 43.2, 61.6, 61.7, 61.9, 62.6, 63.2, 65.4, 65.6, 70.9 (N-CH), 127.0, 127.4, 128.3, 139.4 (Ph), 173.1, 173.5 (C=O); ³¹P NMR (202 MHz, CDCl₃) δ 148.0; HRMS-ESI: [M + H]⁺ calcd for C₅₀H₉₂NO₆P 834.6696; found 834.6696.



O-Benzyl-O-(1-O-(palmitoyl)-2-O-stearoyl-sn-glycer-3-yl)-O-(2,3-di-O-benzyl-sn-glycer-1-yl)phosphate (10a). 1*H*-Tetrazole (2.7 mg, 0.039 mmol) was added to a solution of phosphoramidite (24.0 mg, 0.028 mmol) and 2,3-di-O-benzyl-sn-glycerol **9**³⁸ (9.4 mg, 0.034 mmol) in dry CH₂Cl₂ (2 ml) at 0 °C under nitrogen. The reaction mixture was stirred for 15 min at 0 °C and 2 h at room temperature. The reaction mixture was cooled to 0 °C and *t*-BuOOH (5 M in decane) (4.1 µl, 0.042 mmol) was added to the reaction mixture and stirred for 2 h with warming to room temperature. Excess oxidant was quenched with sodium metabisulfite (1 M, 0.1 ml), the reaction mixture was diluted with CH₂Cl₂, extracted, dried (MgSO₄), filtered and concentrated. The solvent was removed *in vacuo* and the residue was purified by column chromatography on silica gel (35% EtOAc/petroleum ether, 0.5% Et₃N) which resulted in a 1:1 mixture the product and unreacted dibenzyl glycerol, which was directly subjected to hydrogenolysis.

O-Benzyl-O-(1-O-(stearoyl)-2-O-palmitoyl-sn-glycer-3-yl)-O-(2,3-di-O-benzyl-sn-glycer-1-yl)phosphate (10b). Synthesized as for **10c**, 10.2 mg (34%). [α]_D²⁵ +6.2 (*c* = 0.25, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 0.88 (6 H, t, *J* = 6.8 Hz, 2 × CH₃), 1.27 (56 H, m, 28 × CH₂), 1.57 (4 H, m, 2 × COCH₂CH₂), 2.26 (4 H, t, *J* = 7.6 Hz, 2 × COCH₂), 3.56 (2 H, t, *J* = 5.6 Hz, H3'a,3'b), 3.75–3.79 (1 H, m, H2'), 4.03–4.29 (6 H, m, H1'a,1'b,3a,3b,1a,1b), 4.50–4.54 (2 H, m, CH₂Ph), 4.60–4.68 (2 H, m, CH₂Ph), 5.04 (2 H, m, CH₂Ph), 5.13–5.20 (1 H, m, H2), 7.27–7.35 (15 H, m, Ph); ¹³C NMR (126 MHz, CDCl₃) δ 14.2, 22.8, 24.9, 27.2, 29.2, 29.2, 29.4, 29.5, 29.6, 29.7, 29.8, 30.1, 30.2, 32.0, 32.9, 34.1, 34.2, 37.2, 61.8, 65.5, 67.3, 67.3, 69.1, 69.4, 69.4, 69.5, 69.6, 72.3, 73.6, 127.7, 127.8, 127.9, 128.0, 128.5, 128.5, 128.7 (Ph), 172.9, 173.3 (C=O); ³¹P NMR (202 MHz, CDCl₃) δ −1.01, −0.98; HRMS: [M + H]⁺ calcd for C₆₁H₉₇O₁₀P 1021.6853; found 1021.6852.

Triethylammonium O-(1-O-palmitoyl-2-O-stearoyl-sn-glycer-1-yl)phosphate (11a). Synthesized as for **1**, 6.2 mg (27% over 2 steps). [α]_D²⁵ +5.6 (*c* 0.25, CHCl₃); ¹H NMR (400 MHz, CD₃OD : CDCl₃ (1 : 2)) δ 0.84 (6 H, t, *J* = 6.4 Hz, 2 × CH₃), 1.10–1.14 (9 H, m, HN(CH₂CH₃)₃), 1.17–1.36 (56 H, m, 28 × CH₂), 1.52 (4 H, s, 2 × COCH₂CH₂), 2.23 (4 H, dd, *J* = 14.5, 7.2 Hz, 2 × COCH₂), 3.46–3.61 (6 H, s, H3'a,3'b, HN(CH₂CH₃)₃), 3.65–3.73 (1 H, m, H2'), 3.83–3.90 (4 H, m, H1'a,1'b,3a,3b), 3.95 (2 H, m, H3a,3b), 4.11 (1 H, dd, *J* = 12.0, 6.6 Hz, H1b), 5.16 (1 H, s, H2); ¹³C NMR (126 MHz, CD₃OD : CDCl₃ (1 : 2)) δ 14.2, 23.0, 25.2, 25.2, 29.5, 29.5, 29.7, 29.7, 29.9, 30.0, 30.0, 32.3, 34.4, 34.6, 46.5, 62.8, 63.0, 63.7, 66.8, 70.8, 70.9, 71.5, 72.7, 174.0, 174.4; ³¹P NMR (202 MHz, CDCl₃) δ 4.78; HRMS: [M + H]⁺ calcd for C₄₀H₇₉O₁₀P 751.5444; found 751.5444.

O-(1-O-Stearoyl-2-O-palmitoyl-sn-glycer-1-yl)phosphate (11b). Synthesized as for **1**, 9.1 mg (90%). [α]_D²⁵ +4.8 (*c* 0.25, CHCl₃); ¹H NMR (400 MHz, CD₃OD : CDCl₃ (1 : 2)) δ 0.84 (6 H, t, *J* = 6.4 Hz, 2 × CH₃), 1.17–1.36 (56 H, m, 28 × CH₂), 1.57 (4 H, s, 2 × COCH₂CH₂), 2.29 (4 H, dd, *J* = 14.5, 7.2 Hz, 2 × COCH₂), 3.57 (2 H, s, H3'a,3'b), 3.70–3.78 (1 H, m, H2'), 3.84–3.90 (2 H, s, H1'a, H1'b), 3.95 (2 H, m, H3a,3b), 4.15 (1 H, dd, *J* = 11.9, 6.7 Hz, H1b), 4.37 (1 H, m, H1a), 5.20 (1 H, s, H2); ¹³C NMR (126 MHz, CD₃OD : CDCl₃ (1 : 2)) δ 14.2, 23.0, 25.2,

25.2, 29.5, 29.5, 29.7, 29.7, 29.9, 30.0, 30.0, 32.3, 34.4, 34.6, 46.5, 62.8, 63.0, 63.7, 66.8, 70.8, 70.9, 71.5, 72.7, 174.0, 174.4; ³¹P NMR (202 MHz, CDCl₃) δ 5.25; HRMS: [M + H]⁺ calcd for C₄₀H₇₉O₁₀P 751.5444; found 751.5444.

Collision-induced dissociation mass spectrometry of phosphatidylglycerols

Characterization of lipid ions, introduced to a Q Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) *via* nanoESI (nESI) using an Advion Triversa Nanomate (Advion, Ithaca, NY), was performed in negative ionization mode by higher-energy collision induced dissociation (HCD)-tandem mass spectrometry (MS/MS). Deprotonated precursor ions were mono-isotopically isolated using a window of ± 0.5 *m/z*. Product ion spectra were acquired using a mass resolving power of 70 000. Spectra shown are the average of 100 scans.

Conflicts of interest

There are no conflicts to declare

Acknowledgements

We acknowledge the Australian Research Council for financial support (DP160100597). Prof. Gavin Reid and Mengxuan Fang are thanked for assistance with the mass spectrometric analysis of PGs.

References

- 1 S. Furse, *J. Chem. Biol.*, 2017, **10**, 1–9.
- 2 S. E. Horvath and G. Daum, *Prog. Lipid Res.*, 2013, **52**, 590–614.
- 3 I. Van Rhijn, T. van Berlo, T. Hilmenyuk, T. Y. Cheng, B. J. Wolf, R. V. Tatituri, A. P. Uldrich, G. Napolitani, V. Cerundolo, J. D. Altman, P. Willemsen, S. Huang, J. Rossjohn, G. S. Besra, M. B. Brenner, D. I. Godfrey and D. B. Moody, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 380–385.
- 4 R. V. Tatituri, G. F. Watts, V. Bhowruth, N. Barton, A. Rothchild, F. F. Hsu, C. F. Almeida, L. R. Cox, L. Eggeling, S. Cardell, J. Rossjohn, D. I. Godfrey, S. M. Behar, G. S. Besra, M. B. Brenner and M. Brigl, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 1827–1832.
- 5 B. J. Wolf, R. V. Tatituri, C. F. Almeida, J. Le Nours, V. Bhowruth, D. Johnson, A. P. Uldrich, F. F. Hsu, M. Brigl, G. S. Besra, J. Rossjohn, D. I. Godfrey and M. B. Brenner, *J. Immunol.*, 2015, **195**, 2540–2551.
- 6 E. Maloney, D. Stankowska, J. Zhang, M. Fol, Q. J. Cheng, S. Lun, W. R. Bishai, M. Rajagopalan, D. Chatterjee and M. V. Madiraju, *PLoS Pathog.*, 2009, **5**, e1000534.
- 7 M. Jackson, D. C. Crick and P. J. Brennan, *J. Biol. Chem.*, 2000, **275**, 30092–30099.



- 8 P. V. Sarma, L. Srikanth, K. Venkatesh, P. S. Murthy and P. U. Sarma, *Bioinformation*, 2013, **9**, 690–695.
- 9 H. Okuyama, T. Kankura and S. Nojima, *J. Biochem.*, 1967, **61**, 732–737.
- 10 B. ter Horst, C. Seshadri, L. Sweet, D. C. Young, B. L. Feringa, D. B. Moody and A. J. Minnaard, *J. Lipid Res.*, 2010, **51**, 1017–1022.
- 11 F. F. Hsu, J. Turk, R. M. Owens, E. R. Rhoades and D. G. Russell, *J. Am. Soc. Mass Spectrom.*, 2007, **18**, 479–492.
- 12 J. Rossjohn, S. Gras, J. J. Miles, S. J. Turner, D. I. Godfrey and J. McCluskey, *Annu. Rev. Immunol.*, 2015, **33**, 169–200.
- 13 M. V. Dhodapkar and V. Kumar, *J. Immunol.*, 2017, **198**, 1015–1021.
- 14 F. S. Prout, J. Cason and A. W. Ingersoll, *J. Am. Chem. Soc.*, 1948, **70**, 298–305.
- 15 S. Mekala and R. C. Hahn, *J. Org. Chem.*, 2015, **80**, 1610–1617.
- 16 R. P. Linstead, J. C. Lunt and B. C. L. Weedon, *J. Chem. Soc.*, 1951, 1130–1132.
- 17 B. S. Dyer, J. D. Jones, G. D. Ainge, M. Denis, D. S. Larsen and G. F. Painter, *J. Org. Chem.*, 2007, **72**, 3282–3288.
- 18 P. Fodran and A. J. Minnaard, *Org. Biomol. Chem.*, 2013, **11**, 6919–6928.
- 19 X. Liu, B. L. Stocker and P. H. Seeberger, *J. Am. Chem. Soc.*, 2006, **128**, 3638–3648.
- 20 P. S. Patil, T.-J. R. Cheng, M. M. L. Zulueta, S.-T. Yang, L. S. Lico and S.-C. Hung, *Nat. Commun.*, 2015, **6**, 7239.
- 21 B. Cao, X. Chen, Y. Yamaro-Butte, M. B. Richardson, K. L. Martin, G. N. Khairallah, T. W. Rupasinghe, R. M. O'Flaherty, R. A. O'Hair, J. E. Ralton, P. K. Crellin, R. L. Coppel, M. J. McConville and S. J. Williams, *J. Org. Chem.*, 2013, **78**, 2175–2190.
- 22 I. O. Roberts and M. S. Baird, *Chem. Phys. Lipids*, 2006, **142**, 111–117.
- 23 P. D'Arrigo, L. de Ferra, G. Pedrocchi-Fantoni, D. Scarcelli, S. Servi and A. Strini, *J. Chem. Soc., Perkin Trans. 1*, 1996, 2657–2660; R. Sato, Y. Itabashi, H. Fujishima, H. Okuyama and A. Kuksis, *Lipids*, 2004, **39**, 1025–1030.
- 24 P. Woolley and H. Eibl, *Chem. Phys. Lipids*, 1988, **47**, 55–62; R. Wohlgemuth, N. Waespe-Sarcevic and J. Seelig, *Biochemistry*, 1980, **19**, 3315–3321; E. Baer and D. Buchnea, *J. Biol. Chem.*, 1958, **232**, 895–902; R. M. Saunders and H. P. Schwarz, *J. Am. Chem. Soc.*, 1966, **88**, 3844–3847.
- 25 M. H. Caruthers, A. D. Barone, S. L. Beaucage, D. R. Dodds, E. F. Fisher, L. J. McBride, M. Matteucci, Z. Stabinsky and J.-Y. Tang, *Methods Enzymol.*, 1987, **154**, 287–313.
- 26 G. D. Prestwich, *Acc. Chem. Res.*, 1996, **29**, 503–513.
- 27 S. M. Ali, M. U. Ahmad, P. Koslosky, K. Kasireddy, U. Murali Krishna and I. Ahmad, *Tetrahedron*, 2006, **62**, 6990–6997.
- 28 E. N. Jacobsen, F. Kakiuchi, R. G. Konsler, J. F. Larrow and M. Tokunaga, *Tetrahedron Lett.*, 1997, **38**, 773–776.
- 29 C. E. Dreef, C. J. J. Elie, P. Hoogerhout, G. A. van der Marel and J. H. van Boom, *Tetrahedron Lett.*, 1988, **29**, 6513–6515.
- 30 N. J. Jensen, K. B. Tomer and M. L. Gross, *Lipids*, 1987, **22**, 480–489.
- 31 P. B. Smith, A. P. Snyder and C. S. Harden, *Anal. Chem.*, 1995, **67**, 1824–1830.
- 32 F.-F. Hsu and J. Turk, *J. Am. Soc. Mass Spectrom.*, 2000, **11**, 986–999.
- 33 R. V. Tatituri, B. J. Wolf, M. B. Brenner, J. Turk and F. F. Hsu, *Anal. Bioanal. Chem.*, 2015, **407**, 2519–2528.
- 34 W. C. Still, M. Kahn and A. M. Mitra, *J. Org. Chem.*, 1978, **43**, 2923–2925.
- 35 A. B. Pangborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen and F. J. Timmers, *Organometallics*, 1996, **15**, 1518–1520.
- 36 S. Front, N. Court, M.-L. Bourigault, S. Rose, B. Ryffel, F. Erard, V. F. J. Quesniaux and O. R. Martin, *ChemMedChem*, 2011, **6**, 2081–2093.
- 37 G. M. Rankin, B. J. Compton, K. A. Johnston, C. M. Hayman, G. F. Painter and D. S. Larsen, *J. Org. Chem.*, 2012, **77**, 6743–6759.
- 38 N. Chen and J. Xie, *J. Org. Chem.*, 2014, **79**, 10716–10721; C. A. A. van Boeckel, G. M. Visser and J. H. van Boom, *Tetrahedron*, 1985, **41**, 4557–4565.
- 39 Z. J. Wang, N. D. Spiccia, W. R. Jackson and A. J. Robinson, *J. Pept. Sci.*, 2013, **19**, 470.

